Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients

Basit Öğe Kaydı
dc.authoridHacıbekiroğlu, Tuba/0000-0003-1814-5972
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridBaşcı, Semih/0000-0003-4304-9245
dc.authorwosidHacıbekiroğlu, Tuba/ABH-2380-2020
dc.authorwosidUlas, Turgay TU/A-6050-2018
dc.authorwosidKorkmaz, Serdal/IST-3736-2023
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidBaşcı, Semih/AAB-4823-2021
dc.contributor.authorYigenoglu, Tugce Nur
dc.contributor.authorBasci, Semih
dc.contributor.authorSahin, Derya
dc.contributor.authorUlas, Turgay
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorHacibekiroglu, Tuba
dc.date.accessioned2024-08-04T20:50:36Z
dc.date.available2024-08-04T20:50:36Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractSARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARSCoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment.en_US
dc.identifier.doi10.1016/j.transci.2021.103237
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue6en_US
dc.identifier.pmid34419356en_US
dc.identifier.scopus2-s2.0-85113813802en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2021.103237
dc.identifier.urihttps://hdl.handle.net/11616/100172
dc.identifier.volume60en_US
dc.identifier.wosWOS:000733239700018en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMesenchymal stem cellen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectTransfusionen_US
dc.subjectTransplantationen_US
dc.titleMesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patientsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu